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ABSTRACT 
 Although metastasis is the primary cause of cancer deaths and results in 90% of 
all cancer fatalities currently, all attempts to discover anti-metastatic drugs have failed. 
Many of the traditional methods of studying cell migration, using two-dimensional (2D) 
platforms, only study two-dimensional migration, which is fundamentally different and 
more multifaceted than the three-dimensional migration that occurs in vivo. To more 
accurately capture this in vivo variation, we developed a two-and-a-half-dimensional 
(2.5D) cell culture platform to better study three-dimensional (3D) migration. This 
platform consists of a layer of alginate on top of a monolayer of cells grown on tissue 
culture polystyrene (TCPS). To test the parameters of the system, experimentation on 
Human Embryonic Kidney (HEK) 293T cell lines, and linked the 2.5D platform with 
attachment-independent amoeboid migration. U87 glioblastoma cell line proved to 
migrate using similar mechanisms, and was used to test anti-metastatic drug candidates. 
Axitinib, a current chemotherapy drug, blocked migration through pure alginate. 
Additionally, Cilengitide, a failed anti-metastatic drug candidate, was shown to increase 
migration in pure alginate. When attachment-mediated migration was induced, 
Cilengitide did not halt migration, but rather caused the cells to switch to an attachment-
independent mechanisms, which corroborates with Phase II Food and Drug 
Administration (FDA) trials in which Cilengitide failed to stop metastasis. In the study of 
cancer metastasis, this platform can thus be used to not only to explain the failure of past 
clinical trials, but also to discover new anti-metastatic drug candidates. 
Keywords:  Metastasis, Cell Migration, Cancer, Alginate, Drug Testing, Platform 
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INTRODUCTION 
Background/Motivation: 
 Cancer is a leading cause of death in the world, and in 2008 represented 13% of 
all deaths according to the World Health Organization.1 The primary cause of cancer 
deaths is metastasis, or the spread of cancer out of a tumor into another part of the body. 
In fact 90% of all cancer deaths are the result of metastasis, yet no successful anti-
metastatic drugs exist to date.2,3 Currently, all cancer treatments, including surgery, 
radiation, and chemotherapy use the strategy of directly attacking the cancer; however, 
these treatments are often the cause of mortality, and can be more harmful than the 
disease itself. Past attempts to develop anti-metastatic drugs have failed because the 
traditional method of studying cell migration, using two-dimensional platforms, only 
studies two-dimensional migration, which is fundamentally different from the three-
dimensional migration that occurs in vivo. By developing a tool that can aid cancer 
researchers develop anti-metastasis drugs, we can help target the primary cause of cancer 
deaths. 
 
Review of Literature:  
Cell Migration 
 Cell migration is the movement of cells through the combined effort of 
protrusions of the plasma membrane by the actin cytoskeleton and matrix adhesions 
formed by adhesion receptors. These two key processes of migration (protrusion and 
adhesion) consistently rely on a few key proteins. Protrusion is only possible due to actin 
filaments, which formed by actin subunits.4 These filaments are formed in a process 
known as actin polymerization, which starts from an original “pointed” end, where 
subunits slowly fall off, while at the “barbed” end subunits rapidly bind (causing the 
filament to grow) using energy from adenosine triphosphate (ATP) hydrolysis.4 These 
filaments work in tandem with an actin-binding protein, non-muscle myosin II (NM II).5 
NM II cross-links and contracts actin filaments to aid protrusion.5 During adhesion a 
substrate is bound by an adhesion receptor, most of which are integrins, a family of 
binding proteins consisting of heterodimers of α and β subunits.4 Adhesion proteins and 
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protrusion proteins join together at actin-integrin linkages, which have proteins which 
bind to actin or integrin (or both i.e. talin).4 
  
 Migration can occur as a random walk or in response to a stimulus, such as a 
chemoattractant or a stiffness gradient (chemotaxis and durotaxis, respectively). In either 
case, in order to migrate, cells must first develop polarity by organizing the actin 
cytoskeleton so that there is a front, or leading edge, and a rear. When a stimulus 
activates the protein complexes involved in migration and polarization this activation is 
caused by a family of regulators known as Rho guanosinetriphosphatases (Rho 
GTPases).4 For the scope of this paper we need only focus on RhoA and Rac, two of the 
most common Rho GTPases involved in migration.4 In general RhoA and Rac act as 
antagonists, such that when one is highly active the other generally is not; this inverse 
relationship is best thought of as a sort of switching mechanism (the exact pathway is not 
fully understood, but this relationship has been experimentally shown).4,6 
 
Previous Research Focuses on 2D Rather Than 3D 
 Traditionally, most cell migration studies have focused on 2D cell migration 
instead of 3D migration; as a result, 2D migration is a good starting point for further 
understanding migration. 2D migration occurs through discrete steps during which 
protrusions are made at the leading edge, adhesions are generated at the front of the cell 
and eliminated at the back of the cell, and the rear retracts. An apt metaphor for this type 
of motion would be swinging on the monkey bars: you reach forward with one arm and 
grasp the bar in front of you and then you let go of the bar behind you. More technically, 
during 2D migration a flat broad structure at the leading edge known as the lamellum is 
formed through actin polymerization and antiparallel reorganization of actin filaments 
into thick bundles which are crosslinked with NM II.4 At the front of the lemellum is the 
lamellipodia, which contains a branched network of actin filaments.4 The lamellipodia is 
where the primary driving forces of motility occur as new adhesions are made.6 
Activation of the lamellipodia, and by extension the motive force of 2D migration in 
general, is primary driven by Rac; meanwhile retraction of the end of the cell is mediated 
by RhoA.6  
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Limitations of 2D Migration  
 Although 2D migration is comparatively well understood, it is poor 
approximation of the cell’s native behavior inside the organism.7 The cell’s natural 
environment is the extracellular matrix (ECM): a scaffolding made primarily of a 
backbone of protein fibers filled with glycosaminoglycans (typically, proteoglycans) at 
interstitial voids.7 In the laboratory, in vitro experiments on 3D cell migration require the 
use of ECM mimics, known as hydrogels, which are crosslinked networks of hydrophilic 
polymers.7,8,9 Many of these hydrogels are naturally present in the ECM, such as the 
protein collagen or the gycosaminoglycan hyaluronic acid.7 Whether it is ECM in vivo or 
hydrogels in vitro, the density and stiffness of the environment limit the translocation of 
the cell’s nucleus through narrow pores in the scaffold’s structure during 3D migration.8   
 
Possible Solutions 
 There are two ways to handle this physical constraint: either squeeze the nucleus 
through narrow pores (“path finding”), or degrade the ECM to widen pores so that the 
nucleus can easily slide through (“path generating”).8,9 These two forms of 3D migration 
are known as amoeboid migration and mesenchymal migration, respectively.9 
Mesenchymal migration is very similar to 2D migration; the cell is elongated and uses 
high concentrations of adhesions and bundled actin filaments.9 In contrast, amoeboid 
migration is fundamentally different from 2D migration; instead of protrusions resulting 
from flat or elongated bundles of actin filaments, protrusions result from NM II activity 
and are spherical.11,12 These spherical protrusions, or blebs, are formed through 
hydrostatic pressure created by NM II and maintained by cortical tension from actin 
filaments.4,11,12 Finally, unlike 2D migration, which is mediated by Rac, blebbing has 
been shown to be mediated by RhoA, which activates ROCK(Rho-associated Protein 
Kinase) which in turn phosphorylates NM II.5,11,12 
  
 In reality, cells in the body transition between amoeboid and mesenchymal 3D 
migration, and cells are capable of performing both 2D and 3D migration.9,13 These forms 
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of migration can also take place during complex natural phenomena and pathologies, 
such as cancer metastasis. Metastasis is the movement of cells from a primary tumor in 
one location of the body to a secondary site. During metastasis tumors vascularize  
themselves and then tumor cells detach from the surface of the tumor and migrate into 
ECM degraded by proteolysis from matrix metalloproteinases  (MMPs).3,9 In theory, this 
means that during metastasis, cells migrate into a softer ECM; however, there are notable 
exceptions such as breast cancer.3 It is important to note that stiffness plays a significant 
role in this detachment step.3,9 Next, the cell enters the blood stream through invasion, 
which is migration through a thick barrier (in this case the cells of the blood vessels).3 
Then it circulates through the blood stream and enters the tissue at a secondary site to 
form a new tumor.3 Lastly, note that detachment from the tumor involves 3D migration, 
but that cells often use 2D migration to move along the blood vessels when moving to a 
new site.3 
 
Critiques of Current Literature and Technology:  
 Obviously, the complex multi-step process of metastasis cannot be fully simulated 
in vitro; however, since metastasis is a linear sequence of steps, blocking one of them 
could stop this harmful process. Ideally, anti-metastatic drug should target the initial 
migratory step, the 3D migration during detachment from the tumor. Of primary interest 
to this cause is amoeboid migration, which is fundamentally different from both 2D and 
3D mesenchymal migration. By developing a platform to study amoeboid migration, the 
knowledge gained in this endeavor could lead to the development of anti-metastatic 
drugs.  
  
 There are several other migration platforms out there, though none that simulate 
the conditions necessary for amoeboid migration during the detachment step of 
metastasis. Essentially, the dilemma is that, on one hand, time-tested platforms that could 
be used to study potential drug candidates do not permit amoeboid migration and solely 
focus on chemotaxis, rather than stiffness, which is of primary importance during the 
detachment step.3,9,14,15,16 On the other hand 3D platforms focus mainly on invasion, 
rather than detachment amoeboid migration.17 
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Three Classic Migration Platforms  
 Boyden chambers are used for more motile, non-attached cells, forcing their 
migration through an ECM mimic filter, which is great for testing the migration of 
leukocytes and other mobile cells. Since our stated goal is to study migration during the 
detachment of cells during metastasis, Boyden chambers will not work since they 
primarily study invasion.3,14 Dunn chambers allow the use of some attached or unattached 
cells; these cells migrate through small channels between two chambers along a gradient 
of migration-inducing chemicals (i.e. chemotaxis).15 This form is good for studying 2D 
chemotaxis on highly mobile cells, such as macrophages.15 Although Boyden and Dunn 
chambers are commonly used to study migration, their target cell lines (i.e. leukocytes 
and macrophages) are highly motile and very different from most tumor cell lines. The 
third form is capillary migration, where cell from a liquid moves through capillary tube 
up a chemotactic concentration gradient.16 Ultimately, the primary limitation of these 
platforms is their focus on chemotaxis rather than ECM stiffness (especially since Dunn 
chamber and capillary technique lack hydrogels) 
 
3D Platforms  
 There are 3D migration platforms in existence such as the microfabricated 
polyacrylamide channel platform; this particular platform has solid benefits over other 
platforms as it allows for modification of pore size and hydrogel stiffness.17 However, 
this platform focuses on invasion (which has already been heavily studied in Boyden 
chamber), and we are primarily concerned with amoeboid migration during detachment. 
Finally, we could find no 3D platforms that successfully allowed the abrupt transition 
form stiff to soft environment,13,17  as shown in Table 1: 
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 Table 1: Critiques of Current Technologies: This table summarizes the current 
 popular migration platforms and leaves a check mark where desired qualities are 
 met, and an x mark where necessary conditions are not fulfilled. 
 
 
 All of the current migration platforms lack the three key features for focusing 
research on metastasis. First, a low adhesion 3D environment enhances expression of 
amoeboid migration (recall that high adhesion is necessary for mesenchymal migration). 
Second, during metastasis cells are migrating from the tumor into the ECM. Finally, 
stiffness is the key factor in the detachment step of metastasis. 
 
Statement of Project Goal, Objectives, and Expected Results: 
 Herein, we will study amoeboid migration, specifically as an analogue to the 
detachment step of metastasis, by developing a migration platform that has all the 
properties described in Table 1: namely, a low adhesion 3D environment, migration from 
a group of cells, and an abrupt transition from stiff to soft environment. There are three 
milestones in this project: exploration of the migration platform using the HEK cell line, 
verification of the mechanism in U87 glioblastoma, and drug candidate experimentation. 
We expected that the U87 cell line would migrate and that we would be able to accurately 
generate data on drug candidates. 
 
Critiques of Current 
Technologies 
Can use a low-
adhesion 3D 
environment 
Migration away 
from a group of 
cells 
Abrupt 
transition from 
stiff to soft 
environments 
   2D Migration Studies    
   3D Migration Studies    
   Boyden Chamber    
   Dunn Chamber    
   Capillary Technique    
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Backup Plan: 
 Our backup plans were to use different cell lines such as U251 and MDA if U87 
cells failed to migrate. Alternatives to Cilengitide and Axitinib can be found in all three 
appendices (especially Appendix B).  
 
Significance: 
 Metastasis is important because it is the cause of >90% of cancer deaths.3 
Unfortunately, metastasis is not fully understood, and there currently are no anti-
metastatic drugs on the market.2 Ideally, this metastasis platform could generate 
knowledge on amoeboid migration of cancer cells that could be used to select drug 
candidates or lead to the development of a better platform which could do the same. 
 
Team Management: 
 After working together to determine the mechanism of migration we used a 
multipronged approach with a shifting work-load based on individual schedules; by this 
we mean that often times team members were working on different experiments, but were 
able to aid in another’s experiment if a scheduling conflict existed. The goals of the 
project were dynamically re-evaluated as research data was generated. For example, if a 
cell line, inhibitor, or drug candidate showed no results we moved forward to more 
promising avenues of investigation.  
 
Budget for Project: 
 We would like to again thank the Santa Clara School of Engineering, 
Bioengineering Department, and our advisor Dr. Prashanth Asuri for funding this project. 
At no time did we have difficulty paying for reasonable or necessary elements of the 
project. 
 
Timeline for Project:  
 The proposed timeline can be seen in the Gantt chart in Appendix C.  
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DESIGN DESCRIPTION 
 
Overview: 
 Our platform is composed of an alginate layer above TCPS; the softness of the 
alginate and stiffness of the TCPS mimics how a cancer cell moves from the stiffness of a 
tumor to softer healthy tissue. In addition, as alginate has an approximate stiffness of 1 
kPa, our system works well with the specific cancer cell line, U87 glioblastoma, since 
brain tissue has roughly the same stiffness. In order to tailor our design to the needs of 
researchers, we mad our platform easily modifiable for a variety of research models. Our 
choice of alginate allows for future modification with attachment site groups, including 
arginine-glycine-aspartic acid peptide (RGD). Also our system can allow for variable 
stiffness of the bottom TCPS layer using polydimethylsiloxane (PDMS). We verified and 
tested the system using MTT (3-(4,5 – Dimethylthiazol-2yl)-2, 5-diphenyltetrazolium 
bromide (MTT) assays for counting the number of cells in the alginate layer (the cells 
that have migrated or “metastasized”) and those still attached to the TCPS layer, the 
tumor analogue. Furthermore, we applied MTT assays to test inhibitory molecules to 
study anti-metastatic properties of said molecules to demonstrate the validity of our 
design. 
 
Media Protocol (for 15% FBS): 
1. Weigh out 6.39 g Dubecco’s Modified Eagle’s Medium (DMEM)  [w/ glucose] 
and 1.85g NaHCO3 and then pour in graduated cylinder labeled “media” with 409 
ml deionized (DI) water. Mix thoroughly by inversion with parafilm over top of 
cylinder. 
2. Take 75 ml of Fetal Bovine Serum (FBS) (which was thawed over night) and 
solution from (1.) and vacuum filter into 500 ml container. 
3. Add 5ml penicillin/streptomycin, 5.75 ml of nonessential amino acid solution 
(NEAA), and 5.75 ml of Na pyruvate. 
4. Put in fridge overnight before use. 
 
Alginate Protocol (for 3% stock solution): 
1. Fill 50 ml centrifuge tube with 25 ml of DI water and .75g of alginate. 
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2. Place in water bath for 2-3 hours depending on amount of degradation desired. 
3. Autoclave. 
 
Platform Set-Up Protocol (for 48 well plate): 
1. Take 100 mm dish with cells, aspirate media, add 1ml phosphate buffer solution 
(PBS), and tilt flask to cover cells. 
2. Aspirate PBS and add 1ml of room temp trypsin, tilt, and place in incubator for 3 
min. If cells are still attached use cell scraper. 
3. Add 4ml of warm media to dish to wash off cells, place in 15 ml centrifuge tube, 
and centrifuge for 5 min. at 500 RPM. 
4. Aspirate supernatant, and resuspend in 5 ml media. Then take 1ml and place on 
new 100 mm dish and add 9ml media, and store plate in incubator (wait at least 4 
days before repeating process at step 1). 
5. With leftover 4 ml of cells use the hemocytometer to count cell concentration per 
ml by counting the amount of cells in the four corner boxes. The concentration is 
this value ÷ 4 x 104 cells/ml. 
6. With the concentration choose the seeding density desired, then multiply by 24 
wells. This value divided by the concentration in (5) is the volume of solution to 
pour in a new 15 ml centrifuge tube. After that, add enough media for a final 
volume of 7.5 ml. 
7. Plate 300µl of solution from centrifuge tube from (6) into 24 wells of the 48 well 
plate, and then wait approximately 2 days before (8) for cells to attach. 
8. For three wells at a time, pipette out media, while trying to leave just a little at the 
bottom of the well. Then add 300µl alginate solution of the desired concentrations 
(suggested concentrations .25% - 1%). Finally add equal volume of 100mM 
CaCl2. Wait between 2-5 minutes as desired (but be consistent per plate) before 
pipetting out excess CaCl2.  
9. Visually inspect plate and mark wells where too many cells may have been 
pushed up to the top during addition of alginate or CaCl2. If all wells are fine, 
which is unlikely, as you are bound to have some less than perfect wells, be sure 
to eliminate one well to leave room for the blank in step 2 of the MTT protocol. 
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10. Add media with desired drug concentration to top of wells with gelled alginate. 
For our experiments these concentrations are listed in Table 2: 
 
 Table 2: Experimental Drug / Inhibitor Information: This table lists the 
 concentrations used in our experiments, as well as, the company name of the 
 manufacturer. 
Experimental Drug / 
Inhibitor 
Concentration Manufacturer 
NSC23766 100µM EMD Biosciences, La Jolla, 
CA 
Blebbistatin 5µM Cayman Chemical, Ann 
Arbor, MI 
Y27632 16µM Selleck Chemicals, 
Houston, TX 
Cytochalasin D 1µg/ml Enzo Life Sciences, 
Farmingdale, NY 
Cilengitide 25µg/L, 2.5µg/L, 1µg/L MedChem Express, 
Monmouth Junction, NJ 
 
11. After 2 days, remove excess media and add same solution as in (10) (repeat 11 if 
 longer migration period is desired.  
 
MTT Assay Protocol: 
1. After desired migration period has occurred, remove excess media, and add 50X 
of stock tris-acetate-EDTA (TAE) buffer of equal volume (300µl) to each well 
and incubate plate for 20-30 min. 
2. Place solution from each well into individual microcentrifuge tubes, and 
immediately add 200µl of media to bottom of wells that had the samples in them. 
Microcentrifuge the samples for 2 minutes and then remove supernatant and 
resuspend cells in 200µl of media in the empty wells on the plate. Remember to 
add 200µl of media to an empty well as a blank.  
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3. Add 20µl of MTT reagent to each full well and incubate for 4 hours. Then add 
100µl of MTT detergent to lyse cells and wait for at least 3 hrs. or overnight (<12 
hrs.)   
4. When you are ready to take your readings move 100µl of each sample into its 
own well on a corresponding 96 well plate and then perform an absorbance 
reading using the spectrophotometer at 570 nm. 
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Chapter 3: Preliminary HEK Inhibitor Results 
 Initial experiments with the 2.5D metastasis platform were carried out using the 
HEK cells, and while they are not cancer-derived, they are an excellent proof-of-concept 
cell line and were used as such in order to prove and substantiate that quantifiable, 
literature-backed migration was occurring in our system. In order to prove that an 
amoeboid mechanism was being used, we sought to inhibit the activity of key proteins 
related to amoeboid migration. Fortunately, previous experiments beyond the scope of 
this paper, conducted by one of the authors, had provided more details of exactly which 
proteins to inhibit by implicating FBS as a key agent for this migration. FBS is well-
known to provide a plethora of bioactive small molecules and proteins, including those 
which activate the RhoA biochemical signaling pathway and lead to enhanced amoeboid 
migration.18 Since this pathway had already been implicated in migration mechanisms, 
we were able to narrow down the list of candidate proteins to those within the RhoA-
ROCK pathway, including ROCK, NM II (see figure 1). We inhibited Rac1, a protein 
down-regulated during amoeboid migration, as a positive control and actin 
polymerization as a negative one. Figure 2 shows the results of that experiment. 
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 Figure 1: Migration Mechanism: This graphic shows the pathway suggested by 
 the literature and where we inhibited the pathway to verify its accuracy. 
 Pointed arrows imply activation, except for double arrows, which represent 
 equivalence, while the blunted arrows represent inhibition.  
 
 Figure 2: HEK Inhibitor Data: Inhibition of RhoA-ROCK pathway proteins as 
 compared to control.  ROCK, NM II, Actin Polymerization, and Rac1 were 
 inhibited using Y27632, Blebbistatin, Cytochalasin D, and NSC23766 
 respectively. The migration for each  experiment was compared with the 
 unhibited control group to see the relative amount of migration left after 
 inhibition. For each of these experiments, n = 3.  
 
 The inhibition of ROCK, NM II, and actin polymerization leads to substantial 
decreases in migration while Rac1 inhibition appears to have either not affected or 
increased migration; these results match exactly with expectations for amoeboid 
migration. Recall that ROCK activates NM II contractions and thus both lead to increases 
in cytoskeletal tension, composed of actin, within the cell, providing it with the internal 
structure necessary to migration over and through the surrounding environment; thus, 
inhibiting ROCK and NM II removes tension on the actin network, and prevents 
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migration. The inhibition of actin polymerization acted as a negative control, since it 
prevents the actin cytoskeleton from assembling; therefore, without any internal structure 
whatsoever, mammalian cells are unable to migrate regardless of mechanism. Rac1 acted 
a positive control, and was not expected to affected migration. Rac1 acts as a key protein 
activated for attachment-mediated migration and is activated by RhoA, similar to ROCK. 
However, in amoeboid migration Rac1 activity is down-regulated (i.e. inhibited) while 
ROCK activity is up-regulated, while the reverse occurs in attachment-mediated 
migration. Thus the inhibition of Rac1 would be expected to either have no affect on 
migration or slightly increase it as Rac1 became inactive and ROCK became activated. 
The results in figure 2 were thus exactly as expected.  
 This experiment helped to solidly validate that the 2.5D migration platform could 
indeed be used to study amoeboid migration, and potentially open a window to further 
understanding forms of cellular motility 3D.  
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Chapter 4: U87 Glioblastoma Inhibition Results 
 
 To prove the relevance of the 2.5D platform on cancer cell migration and thus its 
relevance to metastases, we expanded to use cancer cells in place of HEKs and attained 
similar results to HEKs. Initial experiments with the U251s, a glioblastoma cell line, and 
MDAs, a breast cancer cell line, failed to show any migration. However, migration was 
observed with another glioblastoma cell line, U87s, that contain a more heterogeneous 
population, including sub-populations with increased motility, which more closely 
mimics in vivo tumors.  
 
 Figure 3: U87 Inhibitor Data: Inhibition of RhoA-ROCK pathway proteins as 
 compared to control. ROCK, NM II, and Rac1 were inhibited using Y27632, 
 Blebbistatin, and NSC23766 respectively. The migration for each experiment was 
 compared with the uninhibited control group to see the relative amount of 
 migration left after inhibition. For each of these experiments, n = 3, and the cells 
 migrated over 4 days.  
  
 The inhibitor studies on U87s matched HEK results, and further proved that our 
system could be used to study cancer amoeboid migration. As with HEK, the inhibition 
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of NM II and ROCK led to much less migration as compared to control.  However, Rac1 
inhibition actually increased migration as compared to control, which was not 
unexpected. As Rac1 must normally be inhibited as ROCK is activated for amoeboid 
migration, the inhibition of Rac1 most likely lead to more activation of ROCK in cells 
that may not have activated ROCK otherwise, thereby causing them to migrate. This data 
thus proves that U87s migrate through a similar pathway to the HEKs as previously 
shown, and that our 2.5D platform can be used to study cancer cell movement.  
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Chapter 5: Anti-metastatic Drug Candidate Results 
 
Since we had established that cancer cell movement was indeed occurring and was 
quantifiable in our system, we screen several promising anti-metastatic drug candidates, 
including Cilengitide and Axitinib, in our system. Cilengitide, cyclic peptide, binds very 
strongly to αvβ3 and αvβ5 integrins, both of which are vital attachment proteins that cells 
use to migrate during traditional, attachment-mediated migration.19 In laboratory tests, 
cilengitide had blocked the migration of cancer cells, and it was proven to have few side 
effects.20,21 However, cilengitide had little to no effect on cancer progression in large 
scale FDA trials, including one with glioblastoma multiforme, the cancer from which the 
U87 cell line was developed.22 On the other hand, axitinib is already cleared as a 
chemotherapy drug that prevents the tumor growth and progression.23 It blocks vascular 
endothelial growth factor (VEGF) receptors, and so prevents the formation of blood 
vessels into the tumor, depriving it of nutrients, halting growth.24 In addition, one study 
saw that Axitinib inhibited cancer cell migration in cancer cells that up-regulated VEGF 
receptor.21 Since U87s had been shown to express VEGF-receptor, we hypothesized that 
Axitinib might inhibit migration in our system.  
  
 When Cilengitide was placed in our system, it greatly increased migration in our 
system, against our expectations. Additionally, the amount of migration was linearly 
related to the concentration of Cilengitide present, as seen in Figure 4. As U87 migration 
had already been proved to follow amoeboid norms, Cilengitide was not expected to have 
a large effect. Figure 6 shows how nearly all of the cells had moved into the alginate in 
the presence of Cilengitide, while in the untreated wells, some cells migrated but a base 
layer of cells remained on the bottom. It appears that blocking integrins in the absence of 
attachment points actually increased amoeboid migration.  
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 Figure 4: Cilengitide Data: Affect of Cilengitide on Migration after four days. 
 Cilengitide was added in three different concentrations, (25 µg/L), medium (2.5 
 µg/L), and low (1 µg/L). The percent migration was calculated as the percent of 
 cells that were in the alginate as compared to the total number of cells. For the 
 control and high group, N = 6. For the medium and low group, N = 5.  
 
 Figure 5: Cilengitide Photos: Pictures of migration through alginate with and 
 without Cilengitide after four days.  A) The view of the bottom of the untreated 
 well, showing a healthy monolayer of U87s. B) The view of the cells suspended 
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 in alginate in the untreated well. A few of the multiple migrated cells within the 
 image are marked with arrows. C) The view of the bottom of the Cilengitide-
 treated well, showing  very few, ill-attached U87s. D). The view of cells 
 suspended in alginate in the Cilengitide-treated well, showing the majority of cells 
 suspended and thus migrated into the well.  
 
 Moving forward, we repeated the experiment using RGD-Alginate to verify the 
effect of Cilengitide in the presence of attachment points. RGD repeat peptides mimic the 
proteins that integrins bind to, and thus by covalently attaching these RGD repeat 
peptides to alginate, we can create a comparable alginate matrix with integrin attachment 
points, which Cilengitide would then be able to inhibit.  
  
 While it is difficult to state with certainty that Cilengitide increased migration 
through RGD-alginate, the cells did seem to switch from the attachment mediated 
migration that took placed in untreated wells to the attachment-independent (or 
mesenchymal), amoeboid migration that was more typical of regular alginate. Though 
migration percentages, shown in Figure 6A, did seem to increase in the presence of 
Cilengitide, all treated wells fell within a standard deviation of the control group.  
Microscopic analysis from Figure 7 are similarly inconclusive in attempting to discern a 
difference in percent migration. Nevertheless, Cilengitide was still affecting the cells, as 
shown by its anti-proliferative effects (Figure 6B). 
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 Figure 6: Cilengitide with RGD Data: The effect of Cilengitide on Migration 
 through RGD-Alginate. A). Percent migration in RGD-Alginate across high (25 
 µg/L), medium (2.5 µg/L), and low (1 µg/L) with N=3. B). Relative number of 
 cells, as measured by total relative absorbance through the MTT assay, for the 
 same wells as in A.  
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 Figure 7: Cilengitide with RGD Photos: Pictures of migration through RGD-
 Alginate with and without Cilengitide. A) The view of the bottom of the untreated 
 well, showing a healthy monolayer of U87s. B) The view of the cells suspended 
 in RGD-Alginate in the untreated well. Cells have migrated throughout the gel, 
 spreading out, attaching, and generating so many shadows they render the picture 
 so blurry. C) The view of the bottom of the Cilengitide-treated well (25 µg/L ), 
 showing a few attached cells  with an arrow. D) The view of cells suspended in 
 alginate in the Cilengitide-treated well. Most cells are group in large clusters at 
 multiple levels.  
 
 However, the migration that occurred in RGD-Alginate without migration was 
decisively different from that occurring in Alginate. While a similar monolayer of cells 
remained on the bottom (Figure 7A), the cells that migrated into the RGD Alginate 
(Figure 7B) migrated uniformly throughout the gel and spread out, showing a 
morphology indicative of attachment points. Because of this attached, spread out 
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morphology and the fact that the cells were uniformly distributed throughout the gel, the 
resulting picture (Figure 7B) had a large amount of shadows, which made the image 
appear blurry. This attached morphology also indicates that the cells moved via 
mesenchymal migration mechnaisms. In the presence of Cilengitide, the migrated cells 
appeared rounded with fewer attachment points (Figure 8D), while very few cells 
remained attached on the bottom of the well (Figure 8C). This migration pattern in the 
presence of Cilengitide was strongly reminiscent of the migration through regular 
alginate as seen in Figure 6, where most cells left the bottom of the well and traveled into 
the alginate in rounded clumps. Thus we surmise that Cilengitide, while it inhibits 
attachment-mediated migration, only causes the cancer cells to switch to attachment-
independent amoeboid migration. 
 As for in the presence of Axitinib, migration through regular alginate was 
strongly inhibited, indicating that it may be a good anti-metastatic drug candidate.  
 
 
 
 
 
 
 
 
 
 
 Figure 8: Axinitib Data: Effect of Axitinib on migration through regular alginate 
 after six days. Due to cell counts below MTT detection limits, the migrated cells 
 were pooled into two wells for the cell counting assay, and the bottom wells N=6 
 was averaged to calculate a relative percent migration between the control and 
 axitinib groups.  
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 Figure 9: Axinitib Photos: Migration in the Presence of Axitinib through alginate 
 after six days. A) Bottom of untreated well. A healthy, dense monolayer is 
 showing, with single cells out of focus since they have begun migrating into the 
 alginate gel and are on a different plane. B) Alginate of untreated well with many 
 single cells that have spread throughout the gel. Some cells are out of focus 
 because they are above or below the focal plane. C) Bottom of well in the 
 presence of Axitinib with a clean monolayer of cells. D) Picture of alginate gel 
 without any cells in the presence of Axitinib. Patchy look comes from light 
 reflecting through the algiante and the bottom monolayer of cells being out of 
 focus. 
 
 While the migration measured through cell counting assays as shown in Figure 8 
reveals that Axitinib caused an approximate 50% decrease in migration, microscopic 
analysis (Figure 10) revealed that there was essentially no migration in the presence of 
Axitinib. In comparison, the U87s migrated and spread out throughout the untreated 
alginate as shown in Figure 10B, and have a rounded morphology, indicative of 
amoeboid attachment-independent migration. Thus, we believe this platform was able to 
prove that Axitinib does indeed inhibit amoeboid migration, and may prove to be a more 
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successful anti-metastatic drug candidate than Cilengitide, which, despite previous in 
vitro tests to the contrary, failed to halt migration in our system.   
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Chapter 6: Summary & Conclusion 
Conclusion: 
 Through this project, we have verified the forms and types of migrations 
occurring in our platform, proven that multiple cell types migrate therein, and tested 
multiple anti-metastatic drug candidates with results matching similar in vivo or in vitro 
experiments from literature, thus proving that our system is indeed an in vitro metastasis 
platform that can help elucidate novel forms of migration as well as screen for novel anti-
metastatic drug candidates. Initial inhibition experiments with HEK cells first proved that 
we were indeed dealing with amoeboid migration when results matched literature-based 
expectations. Experiments fell within expectation again for inhibition experiments with 
U87 glioblastoma cell line, thus proving that cancer cells could also migrate in our 
platform via the same mannerism. Finally, experiments with U87 in the presence of 
Cilengitide and Axitinib tested how our platform could be use to screen for anti-
metastatic drug candidates.  
  
 The use of RGD-alginate further expanded our platform, proving that multiple 
migration mechanisms could be tested therein. Furthermore our system helped provide 
indications of why Phase II trials of Cilengitide have failed in the past; our platform 
allowed us to compare the effect of Cilengitide on both amoeboid and mesenchymal 
forms of migration to show how Cilengitide only inhibits one form. Experiments with 
Axitinib showed that our system could be used to find anti-metastatic drug candidates as 
well, providing much deeper support to the few reports of anti-metastatic activity and 
potentially ensuring that a repeat of the Cilengitide failure does not occur. Thus, we 
proved that our in vitro metastasis platform is not only applicable for in vitro cancer 
migration studies, but provides a much more comprehensive means of screening for anti-
metastatic drugs.  
 
Engineering Standards and Realistic Constraints 
Aesthetics: 
 The audience who might use this platform consists entirely of scientists, and thus 
all aesthetic considerations focus on the technical aspects, involving the simplicity and 
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effectiveness of the system itself, as well as the elegance needed in a persuasive 
presentation of information.  
 
 Table 3: Aesthetic Evaluation Criteria: The aesthetics criteria for our design was 
 based on three major criteria: simplicity, effectiveness, and elegance. These 
 criteria are further broken down into subcriteria in this table. 
 
Simplicity Effectiveness Elegance 
Of  Design In  Qualitative  Measurement In  Persuasive  Presentation 
Of  Use In  Quantitative  Measurement   
  In  Systematic  Methodology   
 
 Simplicity primarily relates to the overall simplicity of design, as well as the 
simplicity with which the system can be. The effectiveness of the system can be 
evaluated by the nature of the qualitative as well as quantitative measurements that 
combine to create a systematic methodology to ensure the accurate results. Since this 
platform needs to be proven, its elegance relies upon the presentation of results and data 
that support its future use.  
 
Simplicity 
 The system is about as simple as possible.  
 
 
 Figure 10: Simplicity of Design: Step by step process describing the protocol for 
 creating our in vitro metastasis platform.  
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 To begin the cells are plated onto the typical plastic cell culture material. In step 
two, alginate is added on top as a liquid and then gelled in step three. After step three, the 
plate is left until cells migrate into the top alginate gel after several days. Each step of the 
process is quite simple; the gelation process itself takes only a matter of minutes with a 
addition of a very easily acquired and prepared chemical. Alginate can also be easily 
modified to introduce biochemical factors or to change the stiffness of the gel. The 
process of gelation can also be undone easily, though not as quickly, with the addition of 
another easily attained chemical. Additionally, the entire process is scalable from 512-
well plates to 10 cm Petri dishes. Finally, all reagents involved in this process are non-
toxic, making chemical handling and safety extremely simple.  
 
Effectiveness  
 The platform is quite effective as a low-budget method to record an 
approximation of three dimensional cell movement. It allows for an ease of 1) qualitative 
measurement as well as 2) quantitative measurement, which creates a 3) systematic 
method and easily track the progress and an experiment and compare results.  
  
 1) Qualitative measurement. The migration occurs off of a fixed surface and is 
clearly visible in a microscope of sufficient magnification.  Typically migration is tracked 
using programmable microscopes that can find the exact same point repeatedly over 
several days to photograph and track migration. While these expensive microscopes 
would help in quantifying migration, they are not required since a stark difference can be 
seen in the plate after simply three days. 
  
 2). Quantitative measurement. That gelation can be reversed means that the gel 
can be easily removed after three days, and an analysis of the number of cells now 
suspended in the dissolved gel can be run. This allows for a quantitative measurement of 
the migration that is independent of any user-bias inherent in qualitative measurements.  
  
 3) Systematic Method. Thus, without the need of any advanced microscopes or 
machinery, easily obtained qualitative observations through a microscope can inform the 
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user, a scientist, when the quantitative measurements should take place. Thus quality 
assurance is inherently a part of the protocol since quantitative measurements are only 
taken when qualitative measurements are indicative of results first. If migration fails to 
initiate, it can be seen immediately in the control group through qualitative observation, 
and if quantitative measurements give a false negative or positive where qualitative 
measurements indicate the opposite, the user can easily know if the experiment needs to 
be repeated or if the variables need to be tweaked to get more accurate quantitative 
results.  These quantitative measurements can thus be used to track the effect of various 
factors on the migration, allowing for the screening of various anti-migration drug 
candidates or the analysis of alginate hydrogel-cell interactions.  
Elegance 
 Since this metastasis platform remains has been, the elegance of our system is 
similarly be vested through the precise evaluation of its effectiveness, as proven by our 
results. For the rapid and elegant presentation of our results, this evaluation was made 
largely in the form of data graphics, with some photographs. According to Edward Tufte, 
the eminent graphical design scholar, “Graphical elegance is often found in simplicity of 
design and complexity of data.”25 Following this vein of thought, our goal was to present 
the complexity of our system and our results via the simplest graphical means possible, 
while eliminating bias. We have attempted to follow some of Tufte’s principles of 
graphical design, including: greater length than height, no legend is necessary, precision 
and clarity in short messages that explain the data, and no 
coloring/shading/crosshatching.  
  
 Furthermore, since we are working with live cells, the most direct method of 
showing our results will be to use some before and after pictures to conclusively show 
that the cells have indeed migrated. Although it would be tedious and unnecessary to 
show photographs for each and every experiment, the selective usage of before and after 
photographs can clearly illustrate the effective nature of the platform to a general 
audience. Our experiments will attempt to correlate our current findings with past 
experiment results, as well as verifying the effectiveness of anti-metastatic drug 
candidates. We will then try to synthesize the data from these experiments into a series of 
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graphs that illustrate the elegance of our system, the continuity between the scientific 
literature and our results, and thus the platform's utility in investigating metastasis. 
 
Ethics:  
 During the design phase of our senior design project, we will be finalizing 
research using HEK 293 cells in an alginate hydrogel. Later in the year we will move 
onto a cancer cell line, specifically the glioblastoma U87. 
  
 As members of Santa Clara University (SCU) we have the responsibility to 
uphold its values which are best stated in the three C’s: competence, compassion, and 
conscience. In competence we will seek to work effectively as a team and uphold 
professional standards. With regards to compassion the primary focus of our design 
project is to study cancer metastasis, and as such we feel we are following the call of 
compassion. In terms of conscience we will seek to address the complex social issues 
involved with our project.  
 
In discussing the ethical considerations for this senior design project, we will explore five 
main categories:  
 Legal concerns 
 The platform/product under development 
 The social considerations of the research 
 The team dynamics for the senior design project 
 The materials and methods used in the research process 
 
 The potential ethical risks involved in this project have been assessed to range 
from no risk, to a medium-low risk. The assessment scale ranges from high risks, which 
are classified as those that involve serious ethical breaches, personal harm, and the 
dissolution of personal relationships; to low risks, which involve no possible ethical 
breaches, personal discomfort, or interpersonal agitation. Table 4 shows the potential 
risk, the potentially impacted audience, and ethical goal and issues for each of the five 
categories. 
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 Table 4: Ethical Risk Assessment: A brief analysis for the risk, audience, and 
 detailed ethical considerations for each of the five main categories of ethical 
 importance to this senior design project. 
Ethical Category 
Risk 
Assessment 
Audience 
Potentially 
Impacted Considerations/Ethical Goal 
Legal Concerns Little/None 
Project team, 
lab, & SCU 
Avoidance of potential patent and 
copyright conflicts  
Platform/Product: 
Health and Safety 
Very Low 
Project Team / 
Potential future    
researchers 
Little / no personal harm possible 
Professional  
Considerations 
Low 
Potential future    
researchers / 
Research 
Community 
Documentation of methods to 
allow for replication of designed 
platform and subsequent analysis; 
Honesty in research; Analysis 
published in good faith. 
Team Dynamics Low/Medium Project team 
Proper communication and work 
sharing 
Methods/Materials Medium 
Project team,  
Lab, & SCU 
Ethically-acquired materials & 
cell lines 
 
 
Legal Concerns 
 Notably, legal concerns are particularly small. All information will be published 
for the scientific community, and thus public knowledge. Additionally, the system is 
entirely experimental, and no involved parties have any interest in investing the number 
of years required to potential develop this platform to the stage of possible deployment or 
company interest. The project is through Dr. Asuri's lab, which is planning to shift the 
focus of this research following the completion of this project because his lab at SCU 
does not have the facilities necessary to push this research further. Additionally, the 
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nature of this system makes even eventual product development highly unlikely; if the 
platform proves to be useful in the broad schemes of scientific research, it will still likely 
not be possible to generate a consumer product just because of the nature of the methods 
involved. 
  
  Furthermore, no involved parties have any business connections, and the senior 
project advisor only has interest in publishing. Beyond a publication, which enhances 
SCU and supports a professor's bid for tenure, SCU's interest stop, especially since the 
professor has not interests in patents. In conclusion, the potential for legal conflicts are 
near none.  
 
Platform/Product and Health and Safety 
 The platform/product under development has a very low risk of breaching any 
health and safety standards. Little to no personal harm is possible; the proper health and 
safety protocols for any scientific environment in which this platform might be used 
would mitigate any possible personal harm. To elaborate, use of fume hoods, aseptic 
technique, closed toe shoes etc. should eliminate almost all health risks.  
 
Professional Considerations 
 The professional considerations for this project engage mainly the scientific 
research community. Ethically, the team has a responsibility to properly document the 
methods to allow future researchers to recreate and perhaps develop further this platform, 
given that the purpose of this research is for further development of humanity's 
knowledge and not for the creation of profits. Following the ethical guidelines for 
Biomedical Engineering Research Obligations as posited by the Biomedical Engineering 
Society in 2004, all research must be published with results of research activity clearly 
delimitated, and research influences properly credited. The senior design team has a 
responsibility to others in the field to accurately and fairly report its findings, to cite 
sources so as to not plagiarize others, and to live up to the highest standards of the field. 
These standards include but are not limited to avoiding research misconduct, which is 
defined as “gross negligence leading to fabrication of scientific message” and 
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“intentional distortion of the research process.”26 Furthermore, the team has a 
responsibility to not deviate from promises to sponsors or declared purposes made during 
applications to grants or additional funding. 
 The risk was marked as low since attempting to get this material published will 
require properly credited and clearly marked research information, and since the team 
project will be striving to adequately test research conclusions to the best of our ability. 
Potential negative side effects of not following this goal include misleading the scientific 
community, which delays the progress of science, and not providing adequate citations, 
thus denying the achievements of other researchers and inadvertently plagiarizing their 
ideas.  Both these issues provide clear negative impacts to individuals and society, and so 
must be avoided. 
 
Team Dynamics: 
 The ethical goals involved in team dynamics are to maintain proper relationships 
between team members, such that work is shared equitably, and friendships built. A 
dissolution of amicable relationships between team members can hobble the success of a 
senior design project, harming both students after their friendship is damaged. Using a 
Kantian ethical model, the dissolution of friendships on the whole would be extremely 
damaging for society, and thus ethically, the dissolution of friendships within the senior 
design team must be avoided, through proper communication of expectations and regular 
meetings to track progress. Additionally, each team member has an ethical responsibility 
to keep the appropriate agreed-upon deadlines and attend team meetings. The project 
should be abandoned under ethical grounds if it exposes team members to harm or 
requires them to perform actions against their moral principles. 
 
Social and Political Implications of Materials & Methods: 
 The acquisition and nature of all materials used in lab was not involved, either 
passively or actively, in generating harm to individuals or society. The methods for the 
research do not involve living animals, and so are unlikely to ever generate ethical issues. 
As for the materials, the SCU guidelines on material acquisition ensure that for the most 
part all materials used in lab are ethically acquired.  
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 However, as a Jesuit institution of learning, SCU has a responsibility to live 
according to certain moral standards. One salient ethical point that arises in our research 
revolves around the use of an old, and extremely common cell line that was original taken 
from a donated legally-aborted fetus over forty years ago. It is known that HEK 293 cells 
were taken from the kidney of a “completely normal” aborted fetus; however, it is not 
known whether the fetus was aborted for natural or elective purposes.27 This leads to 
several ethical dilemmas, but the chief concern must be the ethical nature of elective 
abortions. Recently, contention on campus grounds has been rising over the decision to 
drop elective abortion treatment from faculty and staff health insurance on campus. 
Tensions have risen so high that in protest Stephen Diamond, associate professor of law 
and ethics scholar, has resigned from his position as ethics scholar at the Markkula 
Center for Applied Ethics and roughly 600 members of the community have signed a 
petition.28 Regardless of an individual’s moral stance on abortion, this leads to several 
important questions including whether the institution places a higher premium on the 
pursuit of knowledge and compassion towards others, or whether tradition and 
conscience rule the campus grounds. 
 
            With regards specifically to our project, some might argue that we should simply 
assume, or rather act as if, the HEK 293 cells were part of an elective abortion. Such an 
assumption would go against the general principle, “innocent until proven guilty”; 
however, one may reasonably apply “the well known analogy of a hunter having to be 
sure of his game before firing a shot.”28 If we then apply this analogy and if life begins at 
conception (which would lead us to conclude that all abortion is immoral) then strong 
arguments against the use of HEK 293 cells in research must be considered. 
  
 The strongest of these arguments boils down to a claim that such research 
appropriates benefits from the evil committed by the hypothetical abortion. The primary 
weakness of appropriation of evil arguments is that they tend to argue for a slippery 
slope. In other words, if hypothetically, we learned important knowledge from Nazi 
experiments and we used this knowledge to cure malaria opponents might argue that we 
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may slide into performing immoral experiments ourselves in order to cure future 
diseases. Although slippery slope is a formal fallacy, it is also an important example of a 
human bias, and as such deserves a response. The primary difference between slippery 
slope applied to individual human evils – such as a person who, for example, starts the 
manufacture and sale of illegal drugs to provide for their family and then starts killing 
other drug dealers to protect his territory – and slippery slope applied to societal 
constructs, is that societal constructs tend to have internal self-regulating mechanisms. 
Science, as seen as a large organization of human activity over history, for this reason has 
refrained from falling down the slope. 
 
 Other than the slippery slope fallacy, the main weakness of the appropriation of 
evil arguments is their static deontological stance. Deontology, or “rule-based ethics,” is 
popular among the Catholic Church, and by extension this university, due to its dogmatic 
nature. The difficulty with this form of ethics is that it ignores the consequences of one’s 
actions, which in this case would be to perform medical research efficiently or 
inefficiently and possibly not at all. Furthermore, such a form of ethics ignores the intent 
of the moral agent. As bioengineering students at SCU, we are committed to the pursuit 
of knowledge while being driven by a desire to compassionately help suffering fellow 
humans.   
 
 Furthermore, this project has moved away entirely from this cell line, as well as 
any other that might have been acquired under similar conditions, in order to address any 
possible ethical objections. For the research, cancer cell lines were only used if they were 
taken legally from cancer cell tumors. In this case, it could potentially be argued that the 
removal of these cells even aided the patient.  Thus, the primarily cell lines used present 
no ethical problems. 
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APPENDIX A 
 
Table 5: Drug Categories: This table defines the four potential anti-metastatic drug  
candidate categories. 
 
Type 
Details on mechanism for anti-metastatic 
properties 
VEGF Receptor 
Inhibitor 
Inhibits blood stream supply in vivo, inhibits 
chemicals related to growth and migration. 
Integrin Inhibitor 
Blocks integrins, a key protein used when cells move 
through the body in vivo and in vitro. 
Ruthenium-based 
Ruthenium-based molecule selectively impairs 
certain cellular process, including cellular processes. 
Anti-inflammatory 
Inflammation and invasive cancer recently linked. 
Anti-inflammatory seem to inhibit some cell 
migration.  
 
 These four classes of chemical represent lines of established or developing anti-
metastatic drug research. VEGF receptor inhibitors are commonly used to prevent cancer 
tumors from receiving blood, halting growth. However, recent research has VEGF to be 
related to migration mechanisms as well. Integrin inhibitors have been known to halt 
migration, since integrin proteins on the cell surface are one of the most integral proteins 
necessary for cell migration. Ruthenium-based chemotherapy drugs have come to replace 
previous platinum based drugs, and have shown unique activities that allow more 
selective targeting of cellular processes, including growth and migration. Anti-
inflammatory are the most novel, and only recently discover candidates in the search for 
anti-metastatic agents. Recent research has shown that chronic inflammation can lead to 
the migration and subsequent development of metastatic cancer; furthermore, certain 
anti-inflammatory drugs have been shown to inhibit the key proteins involved in this 
migration, strongly indicating that anti-inflamatory agents may have anti-metastatic 
affects.  
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APPENDIX B 
Table 6: Comprehensive Drug List: This is a fully comprehensive list of future potential 
drug candidates that our platform could test. 
 
Compound Biochemical Affect Current Uses Type 
Y27632 
Inhibits ROCK, stops Rho-
ROCK migration ,echanism Laboratory reagent Organic molecule 
Blebbistatin 
Inhibits Myosin, stops 
contractions necessary for 
migration Laboratory reagent Organic molecule 
NSC23766 
Inhibits Rac protein, stops 
Rho-Rac-mediated migration Laboratory reagent Organic molecule 
Cilengitide 
Inhibits integrins, stop 
certain types of migration 
Potential anti-metastatic 
drug Cyclic peptide 
NAMI-A Chemotherapy drug, general 
Potential anti-metastatic 
drug 
Ruthenium-based 
molecule 
RAPTA-T Chemotherapy drug, general 
Potential anti-metastatic 
drug 
Ruthenium-based 
molecule 
Diosgenin Chemotherapy drug, general 
Potential anti-metastatic 
drug Organic molecule 
Axinitib 
Chemotherapy, VEGF 
Receptor inhibitor, anti-
angiogenic 
Potential anti-metastatic 
drug Organic molecule 
Vatalanib 
Chemotherapy, VEGF 
Receptor inhibitor, anti-
angiogenic 
Potential anti-metastatic 
drug Organic molecule 
Ibuprofen Anti-inflammatory 
Potential chemotherapy 
agent Organic molecule 
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APPENDIX C 
 
 
 
 
Figure 11: Gantt Chart: This Gantt chart was the original research timeline for our  
project. Unfortunately, we were unable to experiment on all of these drug candidates, but  
they are potential areas for future research. 
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